Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Rating of “Hold” from Analysts

Vigil Neuroscience, Inc. (NASDAQ:VIGL) has received a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, Marketbeat reports. Ten analysts have rated the stock with a hold recommendation. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $10.80.

Several research firms recently issued reports on VIGL. JMP Securities restated a “market perform” rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Jefferies Financial Group cut shares of Vigil Neuroscience to a “hold” rating in a research report on Thursday, May 22nd. William Blair lowered shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Mizuho lowered shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Finally, HC Wainwright lowered shares of Vigil Neuroscience from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $14.00 to $8.00 in a research note on Tuesday, May 27th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BVF Inc. IL raised its holdings in Vigil Neuroscience by 121.3% during the first quarter. BVF Inc. IL now owns 4,013,633 shares of the company’s stock worth $7,144,000 after purchasing an additional 2,200,000 shares in the last quarter. 683 Capital Management LLC raised its holdings in Vigil Neuroscience by 24.3% during the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company’s stock worth $3,097,000 after purchasing an additional 340,000 shares in the last quarter. Aberdeen Group plc raised its holdings in Vigil Neuroscience by 226.3% during the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company’s stock worth $3,070,000 after purchasing an additional 1,196,048 shares in the last quarter. Blair William & Co. IL raised its position in Vigil Neuroscience by 219.1% in the 1st quarter. Blair William & Co. IL now owns 1,033,577 shares of the company’s stock valued at $1,840,000 after purchasing an additional 709,677 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its position in Vigil Neuroscience by 16.1% in the 4th quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company’s stock valued at $1,195,000 after purchasing an additional 97,580 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Stock Up 0.3%

Shares of NASDAQ VIGL opened at $7.88 on Tuesday. The firm has a 50-day simple moving average of $4.16 and a 200-day simple moving average of $2.83. The stock has a market capitalization of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 3.43. Vigil Neuroscience has a 52 week low of $1.31 and a 52 week high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, equities research analysts expect that Vigil Neuroscience will post -2.07 EPS for the current year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.